INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States.
| Revenue (Most Recent Fiscal Year) | $0.01M |
| Net Income (Most Recent Fiscal Year) | $-42.08M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1291.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -81592.01% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -119.35% |
| Return on Assets (Trailing 12 Months) | -89.37% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.43 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.93 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 22.98M |
| Free Float | 14.89M |
| Market Capitalization | $169.16M |
| Average Volume (Last 20 Days) | 0.26M |
| Beta (Past 60 Months) | 1.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 35.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |